1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Infections Caused By Picornaviridae - Pipeline Review, H1 2014

Infections Caused By Picornaviridae - Pipeline Review, H1 2014

  • April 2014
  • -
  • Global Markets Direct
  • -
  • 36 pages

Infections Caused By Picornaviridae - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Infections Caused By Picornaviridae - Pipeline Review, H1 2014’, provides an overview of the Infections Caused By Picornaviridae’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Infections Caused By Picornaviridae, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Infections Caused By Picornaviridae and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Infections Caused By Picornaviridae
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Infections Caused By Picornaviridae and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Infections Caused By Picornaviridae products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Infections Caused By Picornaviridae pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Infections Caused By Picornaviridae
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Infections Caused By Picornaviridae pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Infections Caused By Picornaviridae - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Infections Caused By Picornaviridae Overview 6
Therapeutics Development 7
Pipeline Products for Infections Caused By Picornaviridae - Overview 7
Pipeline Products for Infections Caused By Picornaviridae - Comparative Analysis 8
Infections Caused By Picornaviridae - Therapeutics under Development by Companies 9
Infections Caused By Picornaviridae - Therapeutics under Investigation by Universities/Institutes 11
Infections Caused By Picornaviridae - Pipeline Products Glance 13
Early Stage Products 13
Unknown Stage Products 14
Infections Caused By Picornaviridae - Products under Development by Companies 15
Infections Caused By Picornaviridae - Products under Investigation by Universities/Institutes 16
Infections Caused By Picornaviridae - Companies Involved in Therapeutics Development 17
Immunomedics, Inc. 17
Alios BioPharma, Inc. 18
AIMM Therapeutics B.V. 19
Indian Immunologicals Limited 20
Infections Caused By Picornaviridae - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Molecule Type 26
Drug Profiles 28
Picornavirus Nucleoside Analogs - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Virus Protease Inhibitors - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Interferon Lambda-1 Linked Fab Dimer - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Monoclonal Antibodies for Parecho Virus Infections - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Amiloride Derivatives - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Picornaviral Vaccines - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Infections Caused By Picornaviridae - Dormant Projects 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables

Number of Products under Development for Infections Caused By Picornaviridae, H1 2014 7
Number of Products under Development for Infections Caused By Picornaviridae - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Comparative Analysis by Unknown Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Infections Caused By Picornaviridae - Pipeline by Immunomedics, Inc., H1 2014 17
Infections Caused By Picornaviridae - Pipeline by Alios BioPharma, Inc., H1 2014 18
Infections Caused By Picornaviridae - Pipeline by AIMM Therapeutics B.V., H1 2014 19
Infections Caused By Picornaviridae - Pipeline by Indian Immunologicals Limited, H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 23
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Infections Caused By Picornaviridae - Dormant Projects, H1 2014 34

List of Figures

Number of Products under Development for Infections Caused By Picornaviridae, H1 2014 7
Number of Products under Development for Infections Caused By Picornaviridae - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.